Hospital
Cambridge Public Health Commission
Cambridge Public Health Commission was paid $352.57M by Medicaid between Jan 2018 and Dec 2024, across 815 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 14% of everything it billed.
33Billing provider infoCAMBRIDGE PUBLIC HEALTH COMMISSION
CAMBRIDGE, MA 02139
CAMBRIDGE, MA 02139
33aNPI1487603585assigned 05/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$352.57M
24GClaims7,863,886
24DCodes billed815
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#4 of 66
Median peer was paid$29.11M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,070,762 | $48.59M | |
| 2019 | 1,055,055 | $43.32M | |
| 2020 | 891,759 | $42.02M | |
| 2021 | 1,175,693 | $53.32M | |
| 2022 | 1,220,262 | $59.59M | |
| 2023 | 1,309,759 | $53.94M | |
| 2024incomplete | 1,140,596 | $51.80M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 495,297 | 421,088 | $47.72M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 445,242 | 384,457 | $40.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.1% | 189,604 | 167,399 | $24.90M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 126,959 | 114,920 | $18.76M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.1% | 147,864 | 135,254 | $17.91M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.7% | 46,734 | 41,028 | $16.65M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.4% | 287,450 | 187,279 | $8.31M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.0% | 60,214 | 51,145 | $6.91M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.8% | 66,076 | 60,742 | $6.23M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.4% | 51,571 | 40,860 | $4.82M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 70,127 | 61,883 | $4.57M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 90,585 | 36,716 | $4.15M |
803 more codes
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.1% | 53,889 | $4.03M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 27,053 | $3.42M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 37,622 | $3.38M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 30,288 | $3.35M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 22,929 | $3.20M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 8,081 | $3.15M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 6,248 | $3.05M |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 14,848 | $2.98M |
| 93975 | <1% | 30,390 | $2.58M | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 28,747 | $2.51M |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 94,160 | $2.35M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 7,019 | $2.22M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 14,936 | $2.18M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 25,250 | $2.14M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 16,870 | $2.14M |
| 59025 | Fetal non-stress test | <1% | 7,786 | $2.09M |
| 20610 | <1% | 19,053 | $2.04M | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 24,649 | $1.95M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 23,723 | $1.88M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 4,108 | $1.81M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13,271 | $1.69M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 19,731 | $1.65M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14,069 | $1.60M |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 16,507 | $1.54M |
| S9485 | Crisis intervention mental health services, per diem | <1% | 2,812 | $1.49M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 41,694 | $1.47M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 68,993 | $1.42M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 68,980 | $1.41M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 13,307 | $1.37M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,530 | $1.37M |
| 76830 | Ultrasound, transvaginal | <1% | 24,022 | $1.36M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 34,312 | $1.27M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 60,154 | $1.20M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 8,833 | $1.18M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 23,570 | $1.17M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 47,526 | $1.13M |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 2,282 | $1.12M |
| 76801 | <1% | 11,590 | $1.11M | |
| 92588 | <1% | 4,314 | $1.05M | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 3,230 | $1.04M |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 22,860 | $990K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 1,890 | $989K |
| 97161 | <1% | 15,864 | $982K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 174,157 | $981K |
| T1040 | Medicaid certified community behavioral health clinic services, per diem | <1% | 4,757 | $907K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 3,190 | $900K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 11,786 | $892K |
| 52000 | <1% | 2,090 | $883K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,280 | $867K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 1,453 | $860K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 20,874 | $848K |
| 90686 | <1% | 54,363 | $843K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 7,448 | $843K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 5,762 | $834K |
| 86480 | <1% | 22,423 | $834K | |
| 93971 | <1% | 7,479 | $824K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 1,339 | $808K |
| 76770 | <1% | 7,749 | $800K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 16,051 | $799K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 19,697 | $750K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 160,542 | $745K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 14,505 | $742K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 13,565 | $725K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14,384 | $706K |
| 99381 | <1% | 6,625 | $704K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 6,517 | $694K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,566 | $687K |
| 17110 | <1% | 4,239 | $666K | |
| 76642 | <1% | 11,078 | $636K | |
| 99223 | Prolong inpt eval add15 m | <1% | 6,823 | $618K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 10,199 | $616K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 164,894 | $613K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 3,257 | $597K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 76,417 | $594K |
| 12001 | <1% | 3,421 | $578K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,934 | $569K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 68,346 | $564K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 45,638 | $557K |
| 90651 | <1% | 7,060 | $553K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 40,407 | $529K |
| 91322 | <1% | 7,485 | $527K | |
| 58300 | <1% | 4,228 | $518K | |
| 93017 | <1% | 5,907 | $472K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 22,605 | $470K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12,976 | $465K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,341 | $450K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,341 | $442K |
| 80053 | Comprehensive metabolic panel | <1% | 96,804 | $433K |
| 90715 | <1% | 24,110 | $406K | |
| 97803 | <1% | 7,245 | $403K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,985 | $401K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 7,305 | $400K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 10,841 | $394K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 47,796 | $390K |
| 74183 | <1% | 2,109 | $385K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,123 | $375K |
| 76536 | <1% | 5,384 | $370K | |
| 20550 | <1% | 3,097 | $369K | |
| 85027 | <1% | 101,273 | $361K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,696 | $354K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,417 | $352K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 303 | $342K |
| 84484 | <1% | 42,660 | $340K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,772 | $340K |
| 97802 | <1% | 6,156 | $337K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 24,692 | $334K |
| 71250 | <1% | 6,471 | $330K | |
| 81513 | <1% | 3,643 | $315K | |
| 92557 | <1% | 4,890 | $311K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 273 | $310K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 7,781 | $310K |
| 87481 | <1% | 10,327 | $308K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,825 | $303K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 10,149 | $302K |
| 99385 | <1% | 6,644 | $300K | |
| 92558 | <1% | 14,654 | $299K | |
| 86803 | <1% | 40,760 | $296K | |
| 94060 | <1% | 3,615 | $295K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 5,519 | $294K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 16,340 | $288K |
| 90750 | <1% | 7,422 | $286K | |
| 10060 | <1% | 1,836 | $284K | |
| 11981 | <1% | 2,169 | $284K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 79,465 | $282K |
| 87536 | <1% | 5,976 | $276K | |
| 12011 | <1% | 1,514 | $276K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 60,751 | $274K |
| 70498 | <1% | 1,914 | $259K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28,588 | $255K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 13,938 | $254K |
| 90480 | <1% | 9,814 | $253K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 7,253 | $252K |
| 83735 | <1% | 63,648 | $246K | |
| 88142 | <1% | 29,856 | $245K | |
| 99460 | <1% | 2,420 | $243K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 7,237 | $238K |
| 81025 | <1% | 52,360 | $229K | |
| 76870 | <1% | 3,576 | $227K | |
| 92567 | <1% | 7,610 | $227K | |
| 93970 | <1% | 1,954 | $222K | |
| 71045 | Radiologic examination, chest; single view | <1% | 31,765 | $222K |
| 81329 | <1% | 2,343 | $221K | |
| 74178 | <1% | 1,522 | $221K | |
| 87070 | <1% | 33,276 | $221K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 4,330 | $217K |
| ATP08 | <1% | 32,394 | $217K | |
| 99219 | <1% | 13,309 | $214K | |
| 83880 | <1% | 12,805 | $210K | |
| 90677 | <1% | 6,073 | $210K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 11,231 | $204K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 19,023 | $203K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 35,640 | $201K |
| 99205 | Prolong outpt/office vis | <1% | 2,481 | $199K |
| 31575 | <1% | 1,540 | $198K | |
| J3490 | Unclassified drugs | <1% | 17,140 | $198K |
| 88182 | <1% | 3,087 | $198K | |
| 86780 | <1% | 24,266 | $196K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 4,360 | $194K |
| 80050 | General health panel | <1% | 13,906 | $191K |
| ATP14 | <1% | 23,035 | $189K | |
| 87486 | <1% | 6,888 | $188K | |
| 87581 | <1% | 6,890 | $188K | |
| 58301 | <1% | 2,157 | $187K | |
| 31231 | <1% | 1,599 | $185K | |
| 80061 | Lipid panel | <1% | 71,442 | $184K |
| 0124A | <1% | 6,950 | $183K | |
| 83690 | <1% | 38,410 | $179K | |
| G0378 | Hospital observation service, per hour | <1% | 10,858 | $178K |
| 82948 | <1% | 68,497 | $176K | |
| 82728 | <1% | 26,243 | $174K | |
| 97162 | <1% | 3,296 | $169K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 55,865 | $165K |
| 82607 | <1% | 25,163 | $165K | |
| 77062 | <1% | 4,076 | $161K | |
| 0002A | <1% | 4,137 | $161K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 6,944 | $158K |
| 11102 | <1% | 502 | $155K | |
| 0001A | <1% | 4,438 | $154K | |
| 12002 | <1% | 993 | $153K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,905 | $152K |
| 92083 | <1% | 4,597 | $152K | |
| 77080 | <1% | 3,958 | $151K | |
| 73221 | <1% | 1,018 | $151K | |
| 99443 | <1% | 13,950 | $151K | |
| 81003 | <1% | 88,546 | $149K | |
| 73630 | <1% | 17,852 | $149K | |
| 94726 | <1% | 3,484 | $146K | |
| 81514 | <1% | 2,706 | $145K | |
| 87340 | <1% | 26,484 | $144K | |
| 94729 | <1% | 3,069 | $143K | |
| 84702 | <1% | 12,423 | $142K | |
| 70486 | <1% | 3,707 | $141K | |
| 93225 | <1% | 3,250 | $139K | |
| 97165 | <1% | 1,895 | $138K | |
| 57454 | <1% | 827 | $137K | |
| 72197 | <1% | 704 | $132K | |
| 88185 | <1% | 3,640 | $131K | |
| 88184 | <1% | 3,304 | $131K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 2,091 | $128K |
| 11982 | <1% | 1,371 | $127K | |
| 87510 | <1% | 8,505 | $125K | |
| 87660 | <1% | 8,503 | $125K | |
| 93976 | <1% | 4,211 | $122K | |
| 86003 | <1% | 2,099 | $121K | |
| 87480 | <1% | 8,507 | $121K | |
| ATP15 | <1% | 14,237 | $119K | |
| 90670 | <1% | 5,102 | $115K | |
| 73562 | <1% | 14,420 | $114K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 96,825 | $113K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,105 | $112K |
| 86762 | <1% | 12,032 | $112K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 62,173 | $107K |
| 83655 | <1% | 10,226 | $106K | |
| 93350 | <1% | 797 | $104K | |
| 90746 | <1% | 6,969 | $103K | |
| 90714 | <1% | 5,859 | $101K | |
| 86850 | <1% | 14,583 | $95K | |
| 73130 | <1% | 12,752 | $95K | |
| 86706 | <1% | 19,366 | $93K | |
| 94664 | <1% | 7,854 | $93K | |
| 10061 | <1% | 613 | $93K | |
| 64615 | <1% | 341 | $91K | |
| 87186 | <1% | 15,190 | $91K | |
| 99462 | <1% | 2,078 | $90K | |
| 99442 | <1% | 11,161 | $88K | |
| 72100 | <1% | 6,352 | $88K | |
| 58100 | <1% | 888 | $87K | |
| 70491 | <1% | 884 | $87K | |
| 99397 | <1% | 1,923 | $86K | |
| 99386 | <1% | 2,622 | $85K | |
| 73610 | <1% | 13,072 | $85K | |
| 80179 | <1% | 13,593 | $83K | |
| 0054A | <1% | 2,929 | $83K | |
| 73030 | <1% | 12,338 | $83K | |
| 92015 | Determination of refractive state | <1% | 18,721 | $83K |
| 77066 | Tomosynthesis, mammo | <1% | 5,228 | $82K |
| 47562 | <1% | 45 | $81K | |
| 82274 | <1% | 10,527 | $81K | |
| 44970 | <1% | 42 | $81K | |
| 92133 | <1% | 4,777 | $81K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,763 | $80K |
| 86787 | <1% | 10,212 | $80K | |
| 81001 | <1% | 39,742 | $80K | |
| 83970 | <1% | 5,532 | $80K | |
| 29125 | <1% | 1,521 | $79K | |
| 83789 | <1% | 5,150 | $78K | |
| 90656 | <1% | 5,324 | $77K | |
| 90662 | <1% | 10,270 | $76K | |
| 95811 | <1% | 208 | $76K | |
| 84703 | <1% | 13,696 | $76K | |
| 87505 | <1% | 882 | $75K | |
| 73110 | <1% | 9,445 | $74K | |
| 87338 | <1% | 7,146 | $73K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 369 | $73K |
| 99221 | <1% | 1,361 | $72K | |
| 84153 | <1% | 10,109 | $70K | |
| 83605 | <1% | 10,284 | $69K | |
| 0004A | <1% | 1,982 | $68K | |
| 83550 | <1% | 16,157 | $68K | |
| 99464 | <1% | 1,343 | $68K | |
| 93226 | <1% | 2,789 | $67K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,240 | $67K |
| 95886 | <1% | 405 | $67K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,002 | $66K |
| 83540 | <1% | 20,768 | $65K | |
| 82570 | <1% | 28,473 | $65K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 87 | $64K |
| 80076 | <1% | 47,133 | $62K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,213 | $62K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 358 | $61K |
| 90734 | <1% | 1,478 | $60K | |
| 62323 | <1% | 175 | $59K | |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | <1% | 6,637 | $58K |
| 70496 | <1% | 1,862 | $57K | |
| 82043 | <1% | 24,137 | $57K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,577 | $56K |
| 97597 | <1% | 873 | $55K | |
| G0008 | Administration of influenza virus vaccine | <1% | 10,356 | $55K |
| 95806 | <1% | 110 | $55K | |
| 11721 | <1% | 3,811 | $54K | |
| 84403 | <1% | 4,844 | $54K | |
| 0012A | <1% | 2,337 | $53K | |
| 84439 | <1% | 12,725 | $53K | |
| 72141 | <1% | 267 | $52K | |
| 71271 | <1% | 1,146 | $50K | |
| 86682 | <1% | 6,249 | $50K | |
| 84146 | <1% | 5,306 | $49K | |
| 85610 | <1% | 29,984 | $48K | |
| 73502 | <1% | 5,259 | $48K | |
| 0011A | <1% | 2,492 | $47K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,792 | $47K |
| 86592 | <1% | 17,573 | $46K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 52,512 | $46K |
| 0071A | <1% | 1,100 | $46K | |
| 90732 | <1% | 3,965 | $46K | |
| 76376 | <1% | 23,328 | $46K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 20,612 | $45K |
| 69210 | <1% | 1,269 | $43K | |
| 96367 | <1% | 871 | $43K | |
| 87077 | <1% | 8,665 | $43K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 2,259 | $43K |
| 83021 | <1% | 2,885 | $43K | |
| 87517 | <1% | 1,673 | $43K | |
| 86704 | <1% | 8,217 | $43K | |
| 99217 | <1% | 1,190 | $42K | |
| 83718 | <1% | 10,643 | $42K | |
| 90716 | <1% | 1,341 | $42K | |
| 99220 | <1% | 578 | $42K | |
| 92579 | <1% | 386 | $41K | |
| 0072A | <1% | 967 | $41K | |
| 88341 | <1% | 3,126 | $41K | |
| 82746 | <1% | 5,934 | $40K | |
| 73564 | <1% | 6,952 | $40K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,972 | $40K |
| 83001 | <1% | 4,672 | $39K | |
| 83037 | <1% | 20,871 | $39K | |
| 86140 | <1% | 14,013 | $39K | |
| 0064A | <1% | 1,615 | $38K | |
| 85379 | <1% | 5,709 | $38K | |
| 11750 | <1% | 65 | $38K | |
| 87040 | <1% | 4,032 | $38K | |
| 11720 | <1% | 2,347 | $38K | |
| 86900 | <1% | 15,946 | $38K | |
| 76519 | <1% | 699 | $37K | |
| 99383 | <1% | 508 | $37K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 36,540 | $37K |
| 86901 | <1% | 15,938 | $36K | |
| 20605 | <1% | 251 | $36K | |
| 95816 | <1% | 296 | $34K | |
| 73140 | <1% | 5,046 | $34K | |
| 72052 | <1% | 1,468 | $33K | |
| 73080 | <1% | 4,896 | $33K | |
| 80143 | <1% | 10,764 | $32K | |
| 86735 | <1% | 5,567 | $32K | |
| 86765 | <1% | 5,585 | $32K | |
| 52310 | <1% | 52 | $31K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 592 | $31K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 18,187 | $31K |
| 87209 | <1% | 1,608 | $31K | |
| 92134 | <1% | 2,522 | $30K | |
| 92523 | <1% | 176 | $29K | |
| 90707 | <1% | 2,026 | $29K | |
| 0031A | <1% | 972 | $29K | |
| 52356 | <1% | 25 | $29K | |
| 99384 | <1% | 405 | $29K | |
| 77061 | <1% | 800 | $28K | |
| 82950 | <1% | 6,666 | $28K | |
| 92552 | <1% | 222 | $28K | |
| 0003A | <1% | 848 | $28K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 10,199 | $28K |
| 82670 | <1% | 2,199 | $28K | |
| 11056 | <1% | 463 | $27K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 21,801 | $27K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 2,721 | $27K |
| 85651 | <1% | 13,917 | $27K | |
| 83516 | <1% | 3,846 | $27K | |
| 86038 | <1% | 4,915 | $26K | |
| 51729 | <1% | 169 | $26K | |
| 93296 | <1% | 992 | $25K | |
| 90633 | <1% | 2,042 | $25K | |
| ATP09 | <1% | 4,417 | $25K | |
| 86708 | <1% | 4,251 | $24K | |
| 90882 | <1% | 351 | $24K | |
| 95117 | <1% | 1,309 | $24K | |
| 82077 | <1% | 10,041 | $24K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 1,183 | $23K |
| 88342 | <1% | 6,703 | $23K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 3,344 | $22K |
| 0051A | <1% | 598 | $22K | |
| 11100 | <1% | 103 | $22K | |
| 25600 | <1% | 49 | $21K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 16,828 | $21K |
| 83002 | <1% | 2,292 | $21K | |
| 88112 | <1% | 1,364 | $21K | |
| 72170 | <1% | 2,718 | $21K | |
| 82565 | <1% | 10,978 | $21K | |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 346 | $21K |
| J0248 | Injection, remdesivir, 1 mg | <1% | 123 | $20K |
| 74019 | <1% | 2,426 | $20K | |
| 73590 | <1% | 2,855 | $20K | |
| 93308 | <1% | 402 | $20K | |
| 71101 | <1% | 2,643 | $20K | |
| 92250 | <1% | 2,503 | $19K | |
| 85730 | <1% | 6,122 | $19K | |
| 96415 | <1% | 49 | $18K | |
| 72070 | <1% | 1,018 | $18K | |
| 92341 | <1% | 739 | $17K | |
| 10005 | <1% | 62 | $17K | |
| 85007 | <1% | 8,149 | $17K | |
| 50590 | <1% | 12 | $16K | |
| 76377 | <1% | 795 | $16K | |
| 97116 | <1% | 1,093 | $16K | |
| 51798 | <1% | 9,328 | $16K | |
| 87177 | <1% | 1,618 | $15K | |
| 90739 | <1% | 980 | $15K | |
| 85018 | <1% | 7,078 | $15K | |
| 0052A | <1% | 359 | $15K | |
| 73560 | <1% | 1,775 | $14K | |
| 83026 | <1% | 5,555 | $14K | |
| 82105 | <1% | 1,229 | $14K | |
| 83020 | <1% | 1,399 | $14K | |
| 82803 | <1% | 1,117 | $14K | |
| 76000 | <1% | 935 | $14K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,726 | $14K |
| 91307 | <1% | 1,475 | $14K | |
| 87205 | <1% | 5,187 | $14K | |
| 93227 | <1% | 864 | $13K | |
| 86235 | <1% | 1,314 | $13K | |
| 11900 | <1% | 65 | $13K | |
| 88307 | <1% | 561 | $13K | |
| 43235 | <1% | 43 | $13K | |
| 82784 | <1% | 1,670 | $13K | |
| 90474 | <1% | 15,200 | $12K | |
| 82951 | <1% | 843 | $12K | |
| 80159 | <1% | 1,584 | $12K | |
| 99441 | <1% | 1,872 | $12K | |
| 88304 | <1% | 6,450 | $12K | |
| ATP07 | <1% | 1,937 | $12K | |
| 82465 | <1% | 10,070 | $12K | |
| 0053A | <1% | 345 | $12K | |
| 10022 | <1% | 59 | $12K | |
| 93880 | <1% | 166 | $12K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 1,046 | $12K |
| 73090 | <1% | 1,851 | $12K | |
| 92553 | <1% | 227 | $12K | |
| 93224 | <1% | 66 | $12K | |
| 99307 | <1% | 503 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,839 | $11K |
| 84156 | <1% | 5,341 | $11K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,418 | $11K |
| 92002 | <1% | 199 | $11K | |
| 74018 | <1% | 988 | $10K | |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 126 | $10K |
| 99382 | <1% | 147 | $10K | |
| ATP17 | <1% | 1,706 | $10K | |
| 73700 | <1% | 222 | $10K | |
| 76881 | <1% | 174 | $10K | |
| 17000 | <1% | 117 | $10K | |
| 70544 | <1% | 95 | $10K | |
| 82040 | <1% | 5,665 | $10K | |
| 83721 | <1% | 2,401 | $9K | |
| 76857 | <1% | 448 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,602 | $9K |
| 84460 | <1% | 10,945 | $9K | |
| 90632 | <1% | 527 | $9K | |
| 74181 | <1% | 78 | $9K | |
| ATP03 | <1% | 7,614 | $9K | |
| 97035 | <1% | 142 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 550 | $8K |
| 20552 | <1% | 65 | $8K | |
| 93018 | <1% | 958 | $8K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 545 | $8K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 40 | $8K |
| 86160 | <1% | 1,005 | $8K | |
| 86200 | <1% | 1,422 | $8K | |
| ATP16 | <1% | 1,057 | $7K | |
| 84165 | <1% | 1,918 | $7K | |
| ATP11 | <1% | 1,386 | $7K | |
| 90837 | Psychotherapy session, about an hour | <1% | 236 | $7K |
| 90688 | <1% | 698 | $7K | |
| 20611 | <1% | 26 | $7K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 41 | $7K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 141 | $7K |
| 90836 | <1% | 290 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,309 | $7K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 35 | $7K |
| 86665 | <1% | 238 | $6K | |
| 84100 | <1% | 16,592 | $6K | |
| 87255 | <1% | 352 | $6K | |
| 90710 | <1% | 400 | $6K | |
| 88312 | <1% | 2,863 | $6K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,067 | $6K |
| 11719 | <1% | 568 | $6K | |
| 82550 | <1% | 5,889 | $6K | |
| 90696 | <1% | 512 | $6K | |
| 72110 | <1% | 531 | $6K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 6,624 | $6K |
| 99226 | <1% | 101 | $6K | |
| 86618 | <1% | 482 | $6K | |
| ATP02 | <1% | 1,215 | $6K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 10,931 | $5K |
| 77002 | <1% | 213 | $5K | |
| 77049 | <1% | 63 | $5K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12,888 | $5K |
| 88300 | <1% | 997 | $5K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,382 | $5K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,915 | $5K |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 508 | $5K |
| 87081 | <1% | 1,293 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,176 | $5K |
| 87427 | <1% | 651 | $5K | |
| 80178 | <1% | 1,399 | $5K | |
| 90678 | <1% | 288 | $5K | |
| 84450 | <1% | 7,556 | $5K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 8,246 | $5K |
| 80164 | <1% | 794 | $5K | |
| 91306 | <1% | 793 | $5K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 9,370 | $5K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 3,303 | $5K |
| 90713 | <1% | 364 | $4K | |
| 11055 | <1% | 92 | $4K | |
| 73523 | <1% | 249 | $4K | |
| 93228 | <1% | 296 | $4K | |
| 99292 | <1% | 102 | $4K | |
| 57456 | <1% | 32 | $4K | |
| 87902 | <1% | 55 | $4K | |
| 84480 | <1% | 751 | $4K | |
| 73565 | <1% | 1,426 | $4K | |
| 20600 | <1% | 26 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 540 | $4K |
| 98926 | <1% | 69 | $4K | |
| 51784 | <1% | 42 | $4K | |
| V2203 | Spherocylinder, bifocal, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 233 | $4K |
| 86430 | <1% | 1,477 | $4K | |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 308 | $4K |
| 83918 | <1% | 261 | $4K | |
| 26720 | <1% | 13 | $4K | |
| 70547 | <1% | 41 | $3K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 1,867 | $3K |
| 86580 | <1% | 285 | $3K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 469 | $3K |
| 82533 | <1% | 426 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,156 | $3K |
| 74220 | <1% | 41 | $3K | |
| 99310 | Prolong nursin fac eval 15m | <1% | 203 | $3K |
| 86431 | <1% | 1,366 | $3K | |
| H2015 | Community support for mental illness or disability, per 15 minutes | <1% | 104 | $3K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 4,750 | $3K |
| 74174 | <1% | 56 | $3K | |
| 82247 | <1% | 1,393 | $3K | |
| 86593 | <1% | 1,229 | $3K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 76 | $3K |
| 73660 | <1% | 394 | $3K | |
| 94761 | <1% | 29,081 | $3K | |
| 78264 | <1% | 12 | $3K | |
| 82378 | <1% | 676 | $3K | |
| 29130 | <1% | 69 | $3K | |
| 20526 | <1% | 12 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,215 | $3K |
| 96381 | <1% | 300 | $3K | |
| 73060 | <1% | 470 | $3K | |
| 84550 | <1% | 5,415 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 639 | $3K |
| 86376 | <1% | 378 | $3K | |
| 0121A | <1% | 241 | $3K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 4,991 | $2K |
| 87046 | <1% | 400 | $2K | |
| 87045 | <1% | 400 | $2K | |
| 86684 | <1% | 194 | $2K | |
| 86753 | <1% | 710 | $2K | |
| 85045 | <1% | 1,108 | $2K | |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | <1% | 28 | $2K |
| 11976 | <1% | 34 | $2K | |
| 86663 | <1% | 210 | $2K | |
| 36000 | <1% | 3,661 | $2K | |
| 85013 | <1% | 1,003 | $2K | |
| 90691 | <1% | 127 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 987 | $2K |
| 76820 | <1% | 38 | $2K | |
| 99188 | <1% | 1,749 | $2K | |
| 93280 | <1% | 265 | $2K | |
| 99218 | <1% | 47 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,114 | $2K |
| 51702 | <1% | 372 | $2K | |
| 86617 | <1% | 77 | $2K | |
| 82310 | <1% | 1,729 | $2K | |
| 82627 | <1% | 92 | $2K | |
| 99350 | Prolong home eval add 15m | <1% | 46 | $2K |
| 91321 | <1% | 56 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 40 | $2K |
| 99406 | <1% | 721 | $2K | |
| 93229 | <1% | 26 | $2K | |
| 99401 | <1% | 748 | $2K | |
| 90473 | <1% | 441 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 63,210 | $2K |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | <1% | 129 | $2K |
| 76942 | <1% | 106 | $2K | |
| 84144 | <1% | 133 | $2K | |
| 86677 | <1% | 181 | $2K | |
| 73552 | <1% | 254 | $2K | |
| 88173 | <1% | 73 | $2K | |
| 51797 | <1% | 143 | $1K | |
| 73503 | <1% | 321 | $1K | |
| 99349 | <1% | 53 | $1K | |
| 87075 | <1% | 299 | $1K | |
| 36410 | <1% | 53 | $1K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,640 | $1K |
| 86334 | <1% | 217 | $1K | |
| 99225 | <1% | 89 | $1K | |
| 84402 | <1% | 100 | $1K | |
| 84132 | <1% | 1,714 | $1K | |
| 74221 | <1% | 14 | $1K | |
| 93298 | <1% | 40 | $1K | |
| 81050 | <1% | 464 | $1K | |
| 96376 | <1% | 3,772 | $1K | |
| 72050 | <1% | 82 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 312 | $1K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 2,729 | $1K |
| 29515 | <1% | 68 | $1K | |
| 81002 | <1% | 2,948 | $1K | |
| 51741 | <1% | 130 | $1K | |
| V2020 | Frames, purchases | <1% | 122 | $972.84 |
| 98968 | <1% | 109 | $969.81 | |
| 82272 | <1% | 543 | $956.64 | |
| 76981 | <1% | 68 | $906.31 | |
| 90620 | <1% | 13 | $896.09 | |
| 93352 | <1% | 25 | $896.02 | |
| 87563 | <1% | 39 | $866.60 | |
| 86308 | <1% | 209 | $861.80 | |
| A4217 | Sterile water/saline, 500 ml | <1% | 810 | $837.48 |
| 70360 | <1% | 26 | $822.25 | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 14 | $813.30 |
| 85041 | <1% | 562 | $808.05 | |
| 84520 | <1% | 1,234 | $793.85 | |
| 72131 | <1% | 25 | $786.50 | |
| 73200 | <1% | 14 | $774.09 | |
| A4615 | Cannula, nasal | <1% | 719 | $771.46 |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 218 | $727.34 |
| 93288 | <1% | 13 | $703.55 | |
| 69209 | <1% | 33 | $702.44 | |
| 85048 | <1% | 563 | $683.30 | |
| 87538 | <1% | 121 | $680.77 | |
| 99306 | Prolong nursin fac eval 15m | <1% | 41 | $673.59 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,393 | $641.86 |
| 82150 | <1% | 150 | $641.49 | |
| 82360 | <1% | 75 | $639.89 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,273 | $634.00 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 79 | $620.70 |
| 90674 | <1% | 22 | $619.10 | |
| G0237 | Therapeutic procedures to increase strength or endurance of respiratory muscles, face to face, one on one, each 15 minutes (includes monitoring) | <1% | 479 | $617.12 |
| 82248 | <1% | 1,623 | $607.80 | |
| 90839 | <1% | 12 | $600.20 | |
| 86769 | <1% | 16 | $589.82 | |
| 87641 | <1% | 69 | $588.05 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,443 | $552.80 |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 142 | $544.50 |
| 83883 | <1% | 98 | $543.22 | |
| 88141 | <1% | 25 | $532.42 | |
| 87150 | <1% | 954 | $517.77 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 470 | $507.39 |
| 76882 | <1% | 25 | $489.21 | |
| 93297 | <1% | 53 | $478.86 | |
| 86756 | <1% | 43 | $470.40 | |
| 73000 | <1% | 114 | $449.30 | |
| 86705 | <1% | 55 | $447.36 | |
| 83521 | <1% | 430 | $446.72 | |
| 99336 | <1% | 14 | $411.76 | |
| 72082 | <1% | 24 | $409.59 | |
| 99335 | <1% | 18 | $393.39 | |
| 82785 | <1% | 28 | $376.98 | |
| 93041 | <1% | 5,209 | $373.40 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,330 | $351.79 |
| 74175 | <1% | 14 | $351.75 | |
| 73620 | <1% | 112 | $343.58 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 696 | $340.98 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 6,100 | $315.53 |
| 85060 | <1% | 29 | $313.44 | |
| 92555 | <1% | 54 | $302.19 | |
| 86664 | <1% | 29 | $301.74 | |
| 87210 | <1% | 109 | $286.19 | |
| 83615 | <1% | 278 | $281.00 | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 281 | $276.66 |
| 86702 | <1% | 71 | $264.30 | |
| 82977 | <1% | 644 | $259.80 | |
| 87390 | <1% | 15 | $259.52 | |
| 82166 | <1% | 105 | $258.83 | |
| 94375 | <1% | 14 | $255.59 | |
| 83090 | <1% | 43 | $255.29 | |
| 87535 | <1% | 38 | $247.55 | |
| ATP04 | <1% | 64 | $246.16 | |
| 93294 | <1% | 41 | $245.22 | |
| 82010 | <1% | 61 | $214.45 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,074 | $214.32 |
| 86701 | <1% | 71 | $203.45 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 1,773 | $202.91 |
| 99418 | Prolong nursin fac eval 15m | <1% | 15 | $198.51 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 383 | $195.01 |
| 83993 | <1% | 28 | $190.41 | |
| 0013A | <1% | 25 | $183.48 | |
| 82088 | <1% | 20 | $179.70 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 738 | $178.23 |
| 86255 | <1% | 31 | $175.17 | |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care | <1% | 14 | $168.76 |
| 87109 | <1% | 13 | $162.84 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 212 | $155.11 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 403 | $155.11 |
| 88311 | <1% | 184 | $145.70 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 910 | $143.03 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 116 | $120.95 |
| 86880 | <1% | 14 | $114.00 | |
| 87449 | <1% | 30 | $112.01 | |
| 86709 | <1% | 31 | $109.23 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 9,192 | $100.62 |
| 82610 | <1% | 32 | $97.98 | |
| 94760 | <1% | 7,106 | $97.35 | |
| 84244 | <1% | 20 | $97.00 | |
| 91317 | <1% | 205 | $96.66 | |
| 87102 | <1% | 14 | $96.46 | |
| 87640 | <1% | 14 | $92.85 | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 49 | $85.94 |
| 51792 | <1% | 17 | $85.73 | |
| 82103 | <1% | 14 | $83.16 | |
| 84145 | <1% | 276 | $82.83 | |
| 88360 | <1% | 18 | $81.58 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 82 | $81.06 |
| 72202 | <1% | 13 | $70.28 | |
| 90648 | <1% | 3,557 | $68.93 | |
| 82390 | <1% | 15 | $66.42 | |
| 99451 | <1% | 30 | $66.40 | |
| 82960 | <1% | 12 | $64.08 | |
| 93246 | <1% | 20 | $58.31 | |
| 76514 | <1% | 27 | $54.48 | |
| 17003 | <1% | 17 | $54.06 | |
| 93042 | <1% | 26 | $53.92 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 100 | $47.30 |
| 87324 | <1% | 16 | $47.24 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,495 | $41.38 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 855 | $39.46 |
| 83921 | <1% | 17 | $37.41 | |
| 82947 | <1% | 53 | $37.24 | |
| 90685 | <1% | 1,020 | $31.75 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 861 | $27.99 |
| 90611 | <1% | 108 | $23.88 | |
| 36591 | <1% | 266 | $22.00 | |
| 84300 | <1% | 14 | $17.84 | |
| 36416 | <1% | 1,912 | $15.42 | |
| 83695 | <1% | 25 | $12.63 | |
| 91312 | <1% | 3,568 | $12.13 | |
| 84478 | <1% | 110 | $10.12 | |
| 84155 | <1% | 62 | $6.48 | |
| 86364 | <1% | 1,026 | $5.19 | |
| 91301 | <1% | 565 | $3.60 | |
| 82962 | <1% | 24 | $2.42 | |
| A4215 | Needle, sterile, any size, each | <1% | 77 | $1.15 |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 40 | $1.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 171 | $0.01 |
| V2632 | Posterior chamber intraocular lens | 0% | 754 | $0.00 |
| 90723 | 0% | 2,684 | $0.00 | |
| 1123F | 0% | 359 | $0.00 | |
| 90680 | 0% | 2,114 | $0.00 | |
| 90619 | 0% | 72 | $0.00 | |
| A4620 | Variable concentration mask | 0% | 27 | $0.00 |
| A6441 | Padding bandage, non-elastic, non-woven/non-knitted, width greater than or equal to three inches and less than five inches, per yard | 0% | 24 | $0.00 |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | 0% | 208 | $0.00 |
| 90744 | 0% | 357 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 522 | $0.00 |
| 90697 | 0% | 78 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 38 | $0.00 |
| J7110 | Infusion, dextran 75, 500 ml | 0% | 55 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 21 | $0.00 |
| 91305 | 0% | 1,685 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 113 | $0.00 |
| G8952 | Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given | 0% | 596 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 148 | $0.00 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | 0% | 57 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 84 | $0.00 |
| A4657 | Syringe, with or without needle, each | 0% | 886 | $0.00 |
| 91303 | 0% | 123 | $0.00 | |
| 87625 | 0% | 12 | $0.00 | |
| 84075 | 0% | 13 | $0.00 | |
| 0134A | 0% | 15 | $0.00 | |
| G8950 | Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented | 0% | 146 | $0.00 |
| 80320 | 0% | 127 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 145 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 15 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 22 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 12 | $0.00 |
| C1769 | Guide wire | 0% | 12 | $0.00 |
| 87593 | 0% | 12 | $0.00 | |
| 95115 | 0% | 23 | $0.00 | |
| G0010 | Administration of hepatitis b vaccine | 0% | 14 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 16 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 1,141 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 7,522 | $0.00 |
| 0502F | 0% | 219 | $0.00 | |
| A4628 | Oral and/or oropharyngeal suction catheter, each | 0% | 142 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 150 | $0.00 |
| 91300 | 0% | 1,909 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,858 | $0.00 |
| 90700 | 0% | 753 | $0.00 | |
| A4212 | Non-coring needle or stylet with or without catheter | 0% | 19 | $0.00 |
| A4550 | Surgical trays | 0% | 851 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 614 | $0.00 |
| A4618 | Breathing circuits | 0% | 527 | $0.00 |
| S1015 | Iv tubing extension set | 0% | 69 | $0.00 |
| A6403 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 78 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 15 | $0.00 |
| S4005 | Interim labor facility global (labor occurring but not resulting in delivery) | 0% | 320 | $0.00 |
| A4606 | Oxygen probe for use with oximeter device, replacement | 0% | 62 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 57 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 19 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 24 | $0.00 |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 337 | $0.00 |
| A7002 | Tubing, used with suction pump, each | 0% | 43 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 64 | $0.00 |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 1,026 | $0.00 |
| A4208 | Syringe with needle, sterile 3 cc, each | 0% | 60 | $0.00 |
| 88302 | 0% | 106 | $0.00 | |
| 86015 | 0% | 14 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 12 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 15 | $0.00 |
| 81401 | 0% | 12 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEPHEN, NICOLE (INTERIM DIRECTOR MEDICAL STAFF SRV)
| Provider | Location | Paid |
|---|---|---|
| Cambridge Public Health Commission | Cambridge, MA | $9.04M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.